Beta Bionics (NASDAQ:BBNX) Insider Mark Hopman Sells 856 Shares of Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mark Hopman sold 856 shares of the firm’s stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $29.34, for a total transaction of $25,115.04. Following the completion of the sale, the insider directly owned 138,277 shares in the company, valued at $4,057,047.18. This represents a 0.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Mark Hopman also recently made the following trade(s):

• On Wednesday, March 4th, Mark Hopman sold 353 shares of Beta Bionics stock. The stock was sold at an average price of $11.57, for a total transaction of $4,084.21.
• On Monday, March 2nd, Mark Hopman sold 834 shares of Beta Bionics stock. The shares were sold at an average price of $12.36, for a total value of $10,308.24.

Beta Bionics Trading Up 4.6%

BBNX opened at $10.87 on Tuesday. The stock has a market capitalization of $482.41 million, a P/E ratio of -5.57 and a beta of 5.59. The stock has a 50-day moving average price of $15.15 and a 200-day moving average price of $22.01. Beta Bionics, Inc. has a 12-month low of $8.89 and a 12-month high of $32.71.

Beta Bionics (NASDAQ:BBNX) last announced its quarterly earnings data on Tuesday, February 17th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.12. Beta Bionics had a negative net margin of 73.02% and a negative return on equity of 20.29%. The firm had revenue of $32.12 million during the quarter.

Institutional Trading of Beta Bionics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BBNX. GPS Wealth Strategies Group LLC boosted its position in Beta Bionics by 45.0% during the 3rd quarter. GPS Wealth Strategies Group LLC now owns 1,450 shares of the company’s stock valued at $29,000 after acquiring an additional 450 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Beta Bionics by 0.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 331,623 shares of the company’s stock worth $10,105,000 after acquiring an additional 931 shares in the last quarter. Deutsche Bank AG boosted its stake in Beta Bionics by 3.4% during the fourth quarter. Deutsche Bank AG now owns 39,300 shares of the company’s stock worth $1,197,000 after acquiring an additional 1,296 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in Beta Bionics by 203.6% in the third quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock worth $47,000 after purchasing an additional 1,594 shares during the period. Finally, Summit Securities Group LLC purchased a new stake in Beta Bionics in the fourth quarter worth about $52,000.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on BBNX shares. Wall Street Zen downgraded shares of Beta Bionics from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Truist Financial reduced their price objective on Beta Bionics from $37.00 to $25.00 and set a “buy” rating on the stock in a research note on Monday, February 2nd. TD Cowen started coverage on Beta Bionics in a report on Monday, January 26th. They issued a “hold” rating and a $17.00 price objective on the stock. Robert W. Baird lowered their target price on Beta Bionics from $28.00 to $14.00 and set a “neutral” rating for the company in a research note on Wednesday, February 18th. Finally, The Goldman Sachs Group restated a “buy” rating and set a $25.00 target price on shares of Beta Bionics in a report on Thursday, January 15th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $23.20.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.